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Background: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human
cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents
such as pimasertib.
Methods: Patients with KRAS mutant mCRC were treated in the second-line setting with FOLFIRI (5-fluorouracil/folinic acid/
irinotecan) plus pimasertib. The primary objective of the safety run-in phase was to determine the maximum-tolerated dose (MTD)
and the recommended phase II dose of pimasertib combined with FOLFIRI.
Results: Sixteen patients were enrolled in the trial. Ten and six patients were treated daily with 45 and 60mg of pimasertib plus
FOLFIRI, respectively. The MTD was considered to be 45mg per day. The most common treatment-emergent adverse events
were diarrhoea, nausea, vomiting, asthenia and skin/rash event. Of the 15 patients in the efficacy analysis group, two patients had
partial response, nine patients had stable disease, three patients had progressive disease as their best overall response and one
patient could not be evaluated.
Conclusions: Dose escalation of pimasertib in combination with FOLFIRI was limited by toxicity. At the MTD of 45mg per day,
pimasertib was adequately tolerated in patients with mCRC and no unexpected or new safety signals or concerns were identified.
The mitogen-activated protein kinase (MAPK) (RAS/RAF/MEK/
ERK) pathway has a central role in cell-cycle regulation, cell
growth, signalling and survival. The MAPK pathway is frequently
dysregulated and aberrantly activated in human cancers, providing
a strong rationale for developing targeted therapies aimed at
blocking key steps of the pathway (Sebolt-Leopold, 2008; Fremin
and Meloche, 2010; Santarpia et al, 2012). The development of
MEK inhibitors that target effectors with activity downstream of
KRAS may be particularly important for tumours where KRAS is
constitutively activated as a result of mutation because they offer
the potential to expand therapeutic options.
KRAS mutations are common in metastatic colorectal cancer
(mCRC), occurring in B40% of patients (Neumann et al, 2009;
De Roock et al, 2011; Van Cutsem et al, 2011). KRAS status
influences treatment options for patients with mCRC (Van Cutsem
et al, 2010; Schmoll et al, 2012) and this has been well documented
in the case of epidermal growth factor receptor inhibitors, which
are not clinically effective in KRAS mutant (mt) mCRC
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(Bokemeyer et al, 2009, 2012; Van Cutsem et al, 2009, 2011;
De Roock et al, 2010; Douillard et al, 2010, 2013; Ye et al, 2013).
First-line treatment options for patients with KRAS mt mCRC are
5-fluorouracil (5-FU)/folinic acid (FA)/oxaliplatin (FOLFOX),
capecitabine/oxaliplatin (XELOX) or 5-FU/FA/irinotecan (FOL-
FIRI), with or without the vascular endothelial growth factor
inhibitor, bevacizumab (Van Cutsem et al, 2010; Schmoll et al,
2012). The therapeutic options for patients with KRAS mt mCRC
who fail first-line treatment with combination chemotherapy plus
bevacizumab are limited and thus there is an unmet need for new
efficacious agents in the second-line setting for this patient
population (Prenen et al, 2010).
Pimasertib (MSC1936369B/AS703026) is a highly selective,
orally bioavailable, small-molecule inhibitor of the MEK1/2 kinases
of the MAPK pathway, and has demonstrated potent antitumour
activity either alone or in combination with other agents in cell
lines and xenograft models (Clark et al, 2009; Goutopoulos et al,
2009; Machl et al, 2009; Kim et al, 2010; Yoon et al, 2011;
Martinelli et al, 2013). A phase I dose-escalation trial revealed
dose-limiting toxicities of skin rash, acneiform dermatitis, ocular
events and stomatitis (Awada et al, 2012). This trial also showed
that the median plasma half-life was 5 h and that optimal target
suppression and ocular safety were achieved with twice-daily
continuous dosing of pimasertib 60mg. Therefore, a recommended
single-agent pimasertib dose of 60mg twice-daily administered
continuously was selected for phase II trials. Pimasertib is currently
undergoing phase I/II clinical trials in patients with a range of
tumour types and has demonstrated clinical activity both as
monotherapy and in combination with other agents (Ravandi et al,
2011; Delord et al, 2012; Infante et al, 2012; Naing et al, 2012).
A two-part, open-label, multicentre study, comprising a safety
run-in part followed by a randomised phase II part, was designed
to investigate the safety and efficacy of adding pimasertib to
FOLFIRI as second-line treatment for patients with KRAS mt
mCRC. Here, we report the results of the safety run-in part of this
study.
MATERIALS AND METHODS
Study objectives. The primary objective of the safety run-in phase
was to determine the maximum-tolerated dose (MTD) and the
recommended phase II dose (RP2D) of pimasertib combined with
FOLFIRI. Secondary objectives included assessment of the
pharmacokinetics (PK) of pimasertib and irinotecan and evalua-
tion of the antitumour activity of FOLFIRI combined with
pimasertib as second-line treatment for patients with KRAS mt
mCRC.
Patient eligibility. Eligible patients were aged Z18 years
with histologically confirmed KRAS mt mCRC with disease
progressing during or following first-line treatment for metastatic
disease with oxaliplatin plus fluoropyrimidine-based chemotherapy
(with or without bevacizumab). Patients were required to have
measurable metastatic disease according to Response Evaluation
Criteria In Solid Tumours (RECIST v1.0), an Eastern Cooperative
Oncology Group performance status of 1 or less and adequate
hepatic (total bilirubin o1.5 upper limit of normal (ULN), or
aspartate aminotransferase (AST)/alanine aminotransferase
(ALT) o2.5ULN (for subjects with liver involvement, AST/
ALT o5ULN)), renal (serum creatinine o1.5ULN
and/or calculated creatinine clearance (Cockroft–Gault formula)
450mlmin 1) and marrow function (haemoglobin 49.0 g dl 1,
neutrophil count 41.5 109 l 1 and/or platelet count
4100 109 l). Main exclusion criteria comprised retinal degen-
erative disease and history of uveitis or retinal vein occlusion.
Patients should have not received chemotherapy with any
investigational drug or participated in another clinical trial within
4 weeks before study treatment. Enrolled patients were not allowed
to have received radiotherapy on more than 30% of bone marrow
reserves or bone marrow/stem cell transplantation before study
treatment.
Trial design and treatment schedule. This was a two-part, open-
label, multicentre study (four European centres; two in Spain, one
in Belgium and one in Italy), comprising a safety run-in part
followed by a randomised phase II part. Treatment comprised
28-day cycles of FOLFIRI and pimasertib. Patients received
FOLFIRI on days 1 and 15 of each cycle. FOLFIRI comprised
irinotecan (180mgm 2) and FA (l-leucovorin/FA 200mgm 2 or
DL-leucovorin 400mgm 2, 90-min infusion), followed by 5-FU
(400mgm 2 bolus then 2400mgm 2 46-h infusion). Pimasertib,
at a starting dose of 45mg per day, was administered orally on
a 5-day on/2-day off schedule continuously during the cycle (days
1–5, 8–12, 15–19 and 22–26). Beyond cycle 1, patients were
allowed to continue the trial treatment until progressive disease,
intolerable toxicity or investigator/patient decision. The study
protocol was approved by independent ethics committees and
met all legal and regulatory requirements. The study was
conducted in accordance with the Declaration of Helsinki and all
patients provided written, informed consent.
Pimasertib dose escalation. The study used a standard 3þ 3
cohort design, with escalation of pimasertib dose from 45mg per
day in B33% increments until the MTD was reached. Dose
escalation of pimasertib was based on the occurrence of defined
dose-limiting toxicities (DLTs) during cycle 1 of therapy. The
MTD was the dose immediately below the dose associated with
more than one DLT. The MTD cohort was to be expanded to nine
patients to gather more safety information at this dose level. Dose-
limiting toxicities were monitored centrally and the decision to
escalate to the next dose level was taken by a safety monitoring
committee.
Safety. Dose-limiting toxicities were classified according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events v.3.0 and defined as toxicities possibly or probably
related to trial treatments. Dose-limiting toxicities comprised the
following: any non-haematological toxicity of grade 3 or more
(excluding asymptomatic increases in liver function tests reversible
within 7 days and adequately controlled grade 3 vomiting or
diarrhoea); any grade 4 neutropenia of more than 5 days duration
or febrile neutropenia lasting more than 1 day; grade
4 thrombocytopenia (grade 3 if accompanied by bleeding); and
any treatment delay of more than 2 weeks owing to trial treatment-
related adverse events (AEs). Safety parameters in addition to DLT
determination included AEs, deaths, clinical laboratory abnorm-
alities, vital signs and ophthalmologic assessments.
Pharmacokinetics. Plasma samples for PK analysis of pimasertib,
irinotecan/SN-38 and 5-FU were collected at three timepoints
during cycle 1: (i) following administration of single doses of
pimasertib and FOLFIRI on day 1; (ii) following administration of
a single dose of pimasertib on day 8; and (iii) following
administration of a single dose of FOLFIRI on day 15.
Analysis of pimasertib on day 8, following a 2-day period
without pimasertib administration based on the 5-day on/2-day off
schedule, was sufficient to wash out the pimasertib administered
on days 1–5 and all FOLFIRI components administered on day 1.
This was used to characterise pimasertib single-dose PK in patients
with mCRC. An intraindividual crossover comparison of these data
with the PK of single doses of pimasertib in the presence of
FOLFIRI, assessed using samples taken on day 1, was performed to
evaluate any effect of FOLFIRI on the PK of pimasertib. The PK of
pimasertib at steady state was not assessed in this study.
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For the evaluation of the PK of irinotecan and its active
metabolite (SN-38) in the presence (day 1) and absence of
pimasertib (day 15), plasma samples were collected following
a 180mgm 2 irinotecan infusion on days 1 and 15, respectively.
To ensure the absence of pimasertib on day 15, pimasertib dosing
on days 15–19 of cycle 1 was shifted to days 16–20, allowing
a 2-day wash-out period following pimasertib administration
on days 8–12. Intraindividual comparisons were performed to
elucidate the effect of single doses of pimasertib on PK of
irinotecan and SN-38. Pimasertib, irinotecan and SN-38 plasma
concentrations were determined using validated HPLC-MS/MS
methods.
5-fluorouracil concentrations were determined in irinotecan
back-up samples for subjects receiving a 46-h infusion in the
presence (day 1) and absence (day 15) of pimasertib. The samples
were scheduled for 6, 8 and 24 h after the start of irinotecan
infusion. These times corresponded to B4, 6 and 22 h after the
start of the 46-h 5-FU infusion, respectively. The mean apparent
terminal half-life of 5-FU following intravenous administration is
B16min (range 8–20min). The systemic concentration reaches
steady state after 5 half-lives (in this case after about 1.5 h).
Therefore, the selected time points for 5-FU blood sampling
represented steady-state concentrations, which are under the
influence of varying infusion rates by the infusion pump or effect
of concomitantly administered pimasertib. Only a subset of
patients to whom 5-FU was administered using an electronic
pump was analysed, as the variability in 5-FU steady-state
concentrations introduced by other infusion techniques was
considered too high to detect possible effects of pimasertib on
5-FU steady-state concentrations. Intraindividual ratios of 5-FU
concentrations were calculated to assess the impact of pimasertib
on the PK of 5-FU.
Pharmacokinetic parameters were evaluated at Merck Serono
(Darmstadt, Germany) according to standard non-compartmental
methods using the computer program KINETICA, version 4.4.1.
Efficacy. Target and non-target lesions were evaluated at baseline,
every 6 weeks and at the end of treatment by computed
tomography (CT) or magnetic resonance imaging (if the patient
had contraindications to CT) according to RECIST v.1.0. The best
overall response for each patient was defined as the best response
recorded from the start of treatment until disease progression using
RECIST v.1.0.
Statistics. All data analyses for the safety run-in phase of the trial
were descriptive. The DLT analysis set included all patients who
experienced a DLT and those who did not experience a DLT but
received at least 90% of the full planned dose of pimasertib (i.e.,
18 days out of 20 planned) during the first cycle. These patients
should have also received at least two FOLFIRI infusions during
the first cycle independent of whether there were dose delays or
not. Safety data were collected during the first cycle. The safety
analysis set included all patients who received at least one
administration of trial medication (any of the three FOLFIRI
components and pimasertib). The efficacy analysis set included all
patients who received at least one administration of trial
medication (any of the three FOLFIRI components and pimaser-
tib) and had a baseline tumour assessment and at least one
postbaseline efficacy assessment.
RESULTS
Patient disposition. A total of 16 patients were recruited from
March 2010 to May 2012. All patients received study treatment
and were evaluable for safety. Owing to permanent discontinuation
(consent withdrawal, day 12 of cycle 1), one patient (treated with
pimasertib 45mg per day) was excluded from the dose-escalation,
DLT and efficacy analyses (n¼ 15). All patients had at least one
evaluable plasma concentration–time profile, and therefore were
included in the PK analysis set. All treated patients were off
treatment by November 2012. The major reason for patients
ending treatment was disease progression (n¼ 8); other reasons
included withdrawal of consent (n¼ 3) and AEs (n¼ 2).
Patient baseline characteristics. Baseline demographic and clin-
ical characteristics are shown in Table 1. Ten patients (62.5%) had
adenocarcinoma of the colon and six patients (37.5%) had
adenocarcinoma of the rectum. All 16 patients had received at
least one type of prior anticancer therapy. Most patients (n¼ 12;
75%) had received previous chemotherapy for metastatic disease;
four had received prior adjuvant chemotherapy and had mCRC at
study entry. Thirteen patients (81.3%) had received prior surgery
and four patients (25%) had received prior radiotherapy.
Treatment exposure. The median time on trial treatment
(FOLFIRI plus pimasertib) was 10.9 weeks (range 1–44 weeks);
pimasertib 45mg per day cohort: 11.0 weeks (range 1–41 weeks)
Table 1. Patient, disease and treatment characteristics at
baseline (safety population)
Characteristics, n
Pimasertib
45mg per
day (n¼10)
Pimasertib
60mg per
day (n¼6)
Overall
(n¼16)
Sex
Male 5 4 9
Female 5 2 7
Age (years)
Median (range) 60.6 (47–81) 67.6 (38–81) 64.0 (38–81)
ECOG PS
0 6 3 9
1 4 3 7
Location of primary tumour
Adenocarcinoma of
the colon
6 4 10
Adenocarcinoma of
the rectum
4 2 6
Median number of
metastatic sites
(range)
2.0 (2.0–4.0) 1.5 (1.0–2.0) 2.0 (1.0–4.0)
Metastatic sites (n)
Liver 8 5 13
Lung 8 3 11
Lymph nodes 5 1 6
Peritoneum 1 0 1
Bone 1 0 1
Other 1 0 1
Prior treatment
CT for metastatic
disease
7 5 12
Oxaliplatin 7 5 12
5-FU/FA 7 4 11
Capecitabine 0 1 1
Bevacizumab 4 2 6
Other 1 2 3
Radiotherapy 3 1 4
Surgery 9 4 13
Adjuvant CTa 3 1 4
Oxaliplatin 3 1 4
5-FU 2 1 3
Capecitabine 1 0 1
Bevacizumab 1 0 1
Abbreviations: CT¼ chemotherapy; ECOG PS¼Eastern Cooperative Oncology Group
performance status; 5-FU/FA¼ 5-fluorouracil/folinic acid.
aFour patients had received prior adjuvant therapy only. All of these patients had confirmed
metastatic disease at study entry.
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and pimasertib 60mg per day cohort: 9.8 weeks (range
5–44 weeks). The median number of initiated treatment cycles
was 2.5 (range 1–10), with a median of two cycles (range 0–10)
completed. Each cycle was of 4 weeks duration.
Dose-limiting toxicities. Of the 15 patients included in the DLT
analysis set, three experienced a DLT. There were no DLTs in the
first three patients treated with pimasertib 45mg per day, allowing
dose escalation to pimasertib 60mg per day in the next cohort. In
this cohort, two of six patients receiving pimasertib 60mg per day
had DLTs (grade 3 mucositis in both patients). Thus, the MTD for
pimasertib in combination with FOLFIRI was considered to be
45mg per day. Following per protocol expansion of the 45mg per
day dose level from three to nine patients, one of the six additional
patients experienced a DLT (grade 3 hyponatraemia).
Treatment-emergent AEs. All 16 patients had at least one
treatment-emergent AE (TEAE), the majority of which were mild
or moderate in intensity. The most common types of TEAE were
gastrointestinal disorders (diarrhoea: n¼ 13; nausea: n¼ 8; vomit-
ing: n¼ 8), asthenia (n¼ 10) and skin/rash (n¼ 8). Twelve
patients had one or more grade Z3 TEAEs, most frequently
neutropenia (grade 3, n¼ 3; grade 4, n¼ 2), diarrhoea and mucosal
inflammation (both n¼ 3, all grade 3). There were no TEAEs with
a fatal outcome. The three deaths that occurred during the study
were all due to disease progression.
Treatment-emergent AEs considered to be related to pimasertib
occurred in all patients (Table 2). The most frequent of these were
diarrhoea (62.5% of patients), skin/rash (50%), asthenia (37.5%)
and serous retinal detachment (SRD; preferred term for detach-
ment of retinal pigment epithelium and macular degeneration))
(37.5%). The incidence of gradeZ3 pimasertib-related TEAEs was
approximately balanced between the two pimasertib dosing cohorts
(50.0% for the 45mg per day dose and 66.7% for the 60mg per day
dose). Treatment-emergent AEs of special interest, which are class
effects for MEK inhibitors, are shown in Table 3. Seven patients
(43.8%) reported at least one ocular event during trial treatment.
All these events were grade 1, except for a grade 2 SRD reported in
one patient. All the ocular events resolved, except for SRD in two
patients. Nine patients (56.3%) experienced skin/rash events
(Table 3). Two patients receiving pimasertib 60mg per day had
grade 2 events; all other events were grade 1. Treatment-emergent
AEs considered to be related to FOLFIRI occurred in all patients.
Efficacy. Of the 15 patients in the efficacy analysis set, two (13.3%)
had a partial response (PR; one with pimasertib 45mg per day and
one with pimasertib 60mg per day), nine (60.0%) had stable
disease (SD) and three (20.0%) had progressive disease as their best
overall response. Best overall response status was not evaluable for
the remaining patient. Stable disease was maintained for at least
12 weeks in six of nine (66.7%) patients (pimasertib 45mg per day
(n¼ 5) and pimasertib 60mg per day (n¼ 1)).
Pharmacokinetics. In the absence of FOLFIRI, pimasertib was
rapidly absorbed, with median Tmax values in the 45 and 60mg per
day cohorts of 1.5 and 1.25 h, respectively. Maximum plasma
concentrations decreased in a biphasic manner, that is, rapidly up
Table 2. Pimasertib-related treatment-emergent adverse events by worst grade (occurring inZ2 patients overall (all grades) by
preferred term): safety population
Pimasertib 45mg per day (n¼10) Pimasertib 60mg per day (n¼6) Overall (n¼16)
Grade Grade Grade
System organ class preferred term 1/2 3 4 1/2 3 4 1/2 3 4
Patients with Z1 TEAE (by worst grade) 5 5 0 2 2 2 7 7 2
Gastrointestinal disorders (n)
Diarrhoea 4 2 0 4 0 0 8 2 0
Vomiting 2 0 0 3 0 0 5 0 0
Nausea 2 0 0 2 0 0 4 0 0
Stomatitis 1 0 0 2 0 0 3 0 0
Skin and subcutaneous tissue disorders (n)
Rash 4 0 0 4 0 0 8 0 0
Dermatitis acneiform 1 0 0 1 0 0 2 0 0
General disorders and administration site conditions (n)
Asthenia 4 0 0 2 0 0 6 0 0
Mucositis 1 1 0 0 2 0 1 3 0
Eye disorders (n)
Serous retinal detachment 5 0 0 1 0 0 6 0 0
Blood and lymphatic system disorders (n)
Neutropenia 0 0 0 0 1 2 0 1 2
Metabolism and nutrition disorders (n)
Hypomagnesaemia 1 1 0 0 0 0 1 1 0
Abbreviation: TEAE¼ treatment-emergent adverse event. Patients could have more than one event within a system organ class and a preferred term.
Table 3. Treatment-emergent adverse events of special
interest with both doses of pimasertib (safety population)
TEAEs, na Grade 1 Grade 2 Totalb
Ocular TEAEs 7
Serous retinal detachment 6 1 6
Maculopathy 1 0 1
Visual impairment 1 0 1
Visual field defect 1 0 1
Skin/rash TEAEs 9
Rash 8 1 8
Dermatitis 2 1 2
Dry skin 1 0 1
Abbreviation: TEAE¼ treatment-emergent adverse events.
aNumber of patients with at least one TEAE.
bTotal number of patients: each patient had a grade 1 event, with or without a grade 2
event, n¼ 16. Categories based on a selected list of Medical Dictionary for Regulatory
Activities v14 Preferred Terms.
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to 4 h followed by a slower elimination phase. Median apparent
oral clearance (CL/f) of pimasertib was 34.2 and 44.6 l h 1 in the
two cohorts. The median apparent volume of distribution (Vz/f)
largely exceeded total body water, at 265 and 395 l, respectively.
The median apparent pimasertib half-life (t1/2) of pimasertib was
B5 h in both cohorts (Table 4). The PK of pimasertib
administered to colorectal cancer patients at these two dose levels
were consistent with data from the first-in-human (FIH) trial
IMP28062 of pimasertib monotherapy in advanced solid tumour
patients (Houe´de´ et al, 2012).
The observed concentration–time profiles for pimasertib were
consistent in the absence and presence of FOLFIRI (Figure 1A). In
the presence of FOLFIRI, pimasertib maximum plasma concentra-
tions (Cmax) were reduced by 16.3% (range: 0.35–1.18-fold) and
pimasertib exposure (AUC0–N) was reduced by 8.3% (range: 0.74–
1.22-fold) in the 45mg per day cohort. Similar changes were
Table 4. Pharmacokinetics of pimasertib
45mg per day 60mg per day
Day 1
(test)
Day 8
(reference)
Day 1
(test)
Day 8
(reference)
Cmax (ngml
1)
N 9 9 6 6
Median 145 196 386 332
Range 82.3–418 71.6–660 163–516 214–638
Tmax (h)
N 9 9 6 6
Median 2 1.5 0.79 1.25
Range 1.00–6.00 0.53–2.00 0.50–4.00 0.50–2.50
AUC(0–t) (ngml
1 h)
N 9 8 5 5
Median 1120 1270 1390 1260
Range 194–1860 190–2030 666–2190 858–2060
AUC(0–N) (ngml
1 h)
N 7 8 5 5
Median 1160 1340 1430 1340
Range 226–1950 244–2140 673–2310 869–2170
T1/2 (h)
N 7 8 5 5
Median 5.31 5.12 5.56 5.08
Range 2.37–5.97 3.88–7.27 3.53–6.56 4.27–6.25
CL/f (l h1)
N 7 8 5 5
Median 38.7 34.2 42.1 44.6
Range 23.1–199 21.0–184 25.9–89.1 27.6–69.1
Vz/f (l)
N 7 8 5 5
Median 276 265 348 395
Range 197–680 189–1030 210–570 246–425
Ratio of Cmax test/reference
N 8 5
Median 0.837 0.751
Range 0.345–1.18 0.359–2.22
Ratio of AUC(0–N) test/reference
N 7 4
Median 0.917 0.825
Range 0.738–1.22 0.759–1.21
Abbreviations: AUC0–t¼ area under the concentration–time curve from time zero to the
time of last observation; AUC0–N¼ area under the concentration–time curve from time
zero to infinity; CL/f¼ apparent oral clearance; Cmax¼maximal concentration; FOLFIRI¼ 5-
fluorouracil/folinic acid/irinotecan; Tmax¼ time of maximum concentration; t1/2¼ apparent
half-life; Vz/f¼ apparent oral volume of distribution. Pharmacokinetics of pimasertib
following single 45 and 60mg doses on day 1 administered concomitantly with FOLFIRI
(test) and following single 45 and 60mg doses on day 8 administered alone (reference).
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Figure 1. (A) Plasma concentration–time profiles of pimasertib 45mg
per day in the presence (day 1, open diamonds) and absence (day 8,
closed diamonds) of FOLFIRI. Data (mean±s.d.) are shown as semilog
(main figure) and linear (inset) plots. (B) Plasma concentration–time
profiles of irinotecan in the presence (day 1, open diamonds) and
absence (day 15, closed diamonds) of pimasertib 45mg per day. Data
(mean±s.d.) are shown as semilog (main figure) and linear (inset) plots.
(C) Plasma concentration–time profiles of SN-38 in the presence (day 1,
open diamonds) and absence (day 15, closed diamonds) of pimasertib
45mg per day. Data (mean±s.d.) are shown as semilog (main figure)
and linear (inset) plots.
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observed in the 60mg per day cohort (Table 4). These results
indicate that the concomitant administration of FOLFIRI had no
apparent direct effect on the single-dose PK of pimasertib.
The PK of irinotecan and its active metabolite SN-38 in the
absence of pimasertib are shown in Table 5. Irinotecan Cmax levels
were reached 1.5 h after the end of the 90-min infusion. Median
irinotecan CL/f was 23.5 l h 1 (15.6–46.8 l h 1) and median Vz/f
was 212 l (range: 143–382 l). Irinotecan was eliminated with a
median t1/2 of 6.2 h (Table 5).
Intraindividual comparisons to elucidate the effect of single
pimasertib doses on irinotecan and its active metabolite SN-38
showed that the observed concentration–time profiles for both
compounds were consistent in the absence and presence of
pimasertib at both dose levels studied (Figures 1B and C). In the
45mg per day pimasertib cohort, irinotecan Cmax values were
reduced by 2.7% (range: 0.62–1.13-fold) and irinotecan exposure
(AUC0–N) was reduced by 8.9% (range: 0.58–1.08-fold). Similar
changes were observed in the 60mg per day cohort (Table 5).
Formation of irinotecan’s active metabolite SN-38 was not affected
by the coadministration of pimasertib, as evidenced by an increase in
SN-38 Cmax values of 11% (range: 0.912–2.04-fold). Elimination of
SN-38 was also not impacted by concomitant pimasertib adminis-
tration, as evidenced by comparable t1/2 values and a decrease of SN-
38 exposure (AUC0–N) of 9% (range: 0.83–1.58). The data suggest
that single pimasertib doses do not have a direct effect on single-
dose PK of irinotecan and the formation/elimination of its active
metabolite SN-38.
Median intraindividual ratios of 5-FU concentrations in the
presence and absence of pimasertib were 0.86, 0.59 and 0.92 at 6, 8
and 24 h postinfusion start. The data suggest that the administra-
tion of pimasertib did not have an apparent influence on 5-FU
steady-state levels.
DISCUSSION
In this safety run-in part of a phase II study of second-line
treatment in patients with KRAS mt mCRC, dose escalation of
pimasertib from 45 to 60mg per day in combination with FOLFIRI
was limited by toxicity (mucositis). Two patients experienced
a DLT at the pimasertib 60mg per day dose level and therefore the
MTD of pimasertib in this treatment regimen was considered to be
45mg per day, the starting dose level for the dose escalation part of
this trial. There was one additional DLT (grade 3 hyponatraemia)
among the additional six patients in the expanded MTD cohort.
At the MTD of pimasertib 45mg per day in combination with
FOLFIRI, pimasertib was adequately tolerated in patients with
mCRC, and no unexpected or new safety signals or concerns were
identified. The most frequent TEAEs during the study were
diarrhoea and gastrointestinal events. The other frequently
reported grade 1 or 2 events were skin rash, asthenia and SRD.
The most frequent grade 3 or 4 events were mucosal inflammation
and neutropenia. Grade 3/4 mucosal inflammation and neutrope-
nia were not observed as TEAEs in pimasertib monotherapy trials
in patients with advanced solid tumours or haematological
malignancies (Ravandi et al, 2011; Awada et al, 2012), and thus
these TEAEs can be attributed to the combination of FOLFIRI with
pimasertib.
Ocular toxicity is a common feature of most MEK inhibitors
(Renouf et al, 2012). A total of seven patients reported ocular AEs,
none of which were serious. All events were of grade 1 or 2 and all
resolved within 3–139 days from the day of onset, except for SRD in
two patients. The nature, incidence and severity of ocular AEs were
similar to that reported in a previous monotherapy trial of pimasertib
in patients with advanced solid tumours (Awada et al, 2012).
In FIH trials of combination therapies, it is important to control
patient exposure to individual drugs. This allows elucidation of PK
drug–drug interactions that could lead to altered dose–toxicity
relationships when drugs are used in combination, potentially
requiring changes to the dose-escalation scheme. In this study,
coadministration of FOLFIRI did not affect the PK of single-dose
pimasertib. Likewise, single doses of pimasertib of 45 and 60mg
per day influenced the PK of neither irinotecan nor its active
metabolite/SN-38, indicating that pimasertib does not exert
a direct effect on the enzymes involved in the elimination of
irinotecan, that is, CYP3A4 and UGT1A1, or human carboxyles-
terase HCE-2, which catalyses the formation of SN-38. In addition,
pimasertib had no apparent effect on steady-state 5-FU levels.
This corroborates in vitro data showing that pimasertib does not
alter 5-FU metabolism in human liver microsomes (Merck, data on
file). It needs to be noted that the PK evaluations in the present
study were limited to two doses of pimasertib in a small number of
subjects and were not statistically powered to observe predefined
Table 5. Pharmacokinetics of irinotecan and SN-38
Irinotecan SN-38
Day 1
(test)
Day 15
(reference)
Day 1
(test)
Day 15
(reference)
Cmax (ngml
1)
N 10 8 10 8
Median 2070 2120 20.4 15.1
Range 1590–3060 1760–2840 11.4–37.6 9.28–37.5
Tmax (h)
N 10 8 10 8
Median 1.5 1.54 1.5 1.6
Range 1.25–2.50 1.50–2.50 1.50–2.25 1.50–2.50
AUC(0–t) (ngml
1 h)
N 10 8 10 8
Median 10 500 12700 150 146
Range 7130–18 500 7040–17 900 35.4–380 42.5–380
AUC(0–N) (ngml
1 h)
N 9 8 10 7
Median 10 600 13600 198 206
Range 7650–20 600 7330–20 400 102–550 64.7–508
T1/2 (h)
N 9 8 10 7
Median 6.43 6.21 13.6 15.7
Range 5.32–7.63 5.54–8.77 7.10–21.5 4.63–34.2
CL/f (l h1)
N 9 8
Median 29.4 23.5 NC NC
Range 16.4–47.0 15.6–46.8
Vz/f (l)
N 9 8
Median 297 212 NC NC
Range 147–455 143–382
Ratio of Cmax test/reference
N 8 8
Median 0.973 1.11
Range 0.623–1.13 0.912–2.04
Ratio of AUC(0–N) test/reference
N 8 7
Median 0.911 0.91
Range 0.577–1.08 0.825–1.58
Abbreviations: AUC0–t¼ area under the concentration–time curve from time zero to the
time of last observation; AUC0–N¼ area under the concentration–time curve from time zero
to infinity; CL/f¼ apparent oral clearance; Cmax¼maximal concentration; NC¼ not
calculated; t1/2¼ apparent half-life; Tmax¼ time of maximum concentration; Vz/f¼ apparent
oral volume of distribution. Pharmacokinetics of irinotecan and its active metabolite SN-38
following single 180mgm 2 doses on day 1 administered concomitantly with pimasertib
(test) and following single 180mgm 2 doses on day 15 administered alone (reference).
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differences in exposure. This limitation was due to the nature of
the study being a FIH trial. The intraindividual crossover analysis
implemented in this study to elucidate pimasertib’s effects on the
PK of irinotecan/SN-38 and 5-FU, as well as effects of FOLFIRI on
the PK of pimasertib in expanded cohorts, however, provides
higher statistical power because interindividual variability in the
PK of the studied agents can be ignored.
The majority of patients experienced SD (nine patients) and two
patients had PR as their best overall tumour response. Further-
more, for six patients with SD as their best response, the SD was
maintained for at least 12 weeks. The best overall response
spectrum did not seem to differ much between the two pimasertib
doses (45 or 60mg per day) combined with FOLFIRI, suggesting
antitumour activity at both doses. However, the estimated
probability of observing significant clinical benefit with the
combination of pimasertib 45mg per day combined with FOLFIRI
compared with FOLFIRI alone was considered to be low. Thus, the
decision was made not to perform the randomised, placebo-
controlled phase II part of the study.
The optimal approach to targeting the MAPK pathway in
colorectal cancer is not yet established. Further studies are required
to determine the most effective regimens for agents such as MEK1/2
inhibitors (as monotherapy and/or in combination with both
established and emerging therapies) (Troiani et al, 2014) as well as
identifying the patient populations most likely to benefit from such
interventions (Chapman and Miner, 2011).
In conclusion, in combination with FOLFIRI, dose escalation of
the MEK1/2 inhibitor pimasertib from 45 to 60mg per day was
limited by toxicity. Progression to phase II was not recommended
because the potential activity of pimasertib 45mg per day,
administered intermittently, with FOLFIRI was not considered to
be sufficient. Alterations in the PK of pimasertib, irinotecan/SN-38
and 5-FU can be excluded as the underlying reason for
intolerability of the combination.
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